Substance Balance Trial of Methoxyethyl Etomidate Hydrochloride

Summary

This study was a single-center, single-dose, open-label design with 6-8 healthy adult male subjects to evaluate the body material balance of \[14C\]ET-26. Each subject received a single intravenous injection of \[14C\]ET-26 at a dose of 50 µCi/48 mg. Blood, urine, and stool samples were collected at specified times during the study. The pharmacokinetic parameters were calculated, and the distribution of total radioactivity in venous whole blood and plasma was analyzed. The excretion rate and pathway were analyzed. The metabolic pathway and elimination pathway of ET-26 in human body were analyzed.

Timeline

Start

2023-07-17

Primary completion

2023-07-31

Completion

2023-07-31

Drugs

Indications

No indication recorded.